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ABSTRACT Inhaled corticosteroid/long-acting β2-agonist combination therapy is a recommended
treatment option for patients with chronic obstructive pulmonary disease (COPD) and increased
exacerbation risk, particularly those with elevated blood eosinophil levels. SOPHOS (NCT02727660)
evaluated the efficacy and safety of two doses of budesonide/formoterol fumarate dihydrate metered dose
inhaler (BFF MDI) versus formoterol fumarate dihydrate (FF) MDI, each delivered using co-suspension
delivery technology, in patients with moderate-to-very severe COPD and a history of exacerbations.
In this phase 3, randomised, double-blind, parallel-group, 12–52-week, variable length study, patients
received twice-daily BFF MDI 320/10 µg or 160/10 µg, or FF MDI 10 µg. The primary endpoint was
change from baseline in morning pre-dose trough forced expiratory volume in 1 s (FEV1) at week 12.
Secondary and other endpoints included assessments of moderate/severe COPD exacerbations and safety.
The primary analysis (modified intent-to-treat) population included 1843 patients (BFF MDI 320/10 µg,
n=619; BFF MDI 160/10 µg, n=617; and FF MDI, n=607). BFF MDI 320/10 µg and 160/10 µg improved
morning pre-dose trough FEV1 at week 12 versus FF MDI (least squares mean differences 34 mL
[p=0.0081] and 32 mL [p=0.0134], respectively), increased time to first exacerbation (hazard ratios 0.827
[p=0.0441] and 0.803 [p=0.0198], respectively) and reduced exacerbation rate (rate ratios 0.67 [p=0.0001]
and 0.71 [p=0.0010], respectively). Lung function and exacerbation benefits were driven by patients with
blood eosinophil counts ⩾150 cells·mm−3. The incidence of adverse events was similar, and pneumonia
rates were low (⩽2.4%) across treatments.
SOPHOS demonstrated the efficacy and tolerability of BFF MDI 320/10 µg and 160/10 µg in patients
with moderate-to-very severe COPD at increased risk of exacerbations.
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The Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends the use of an inhaled
corticosteroid (ICS) as an add-on treatment with a long-acting β2-agonist (LABA) for patients with
chronic obstructive pulmonary disease (COPD) who experience exacerbations despite long-acting
bronchodilator monotherapy; particularly when they have elevated blood eosinophil levels [1]. Clinical
studies have demonstrated that ICS/LABA combination therapy can improve lung function and reduce
COPD exacerbation rates more effectively than LABA monotherapy [2–11].
The budesonide/formoterol fumarate dihydrate metered dose inhaler (BFF MDI) is an ICS/LABA
fixed-dose combination that is formulated using innovative co-suspension delivery technology. Unlike
drug crystal-only suspensions, co-suspension delivery technology enables reliable aerosol performance and
consistent drug delivery, even in the presence of simulated patient-handling errors [12, 13].
The recently completed phase 3 TELOS study (NCT02766608), conducted in patients with
moderate-to-very severe COPD who were not required to have an exacerbation history, demonstrated that
BFF MDI 320/10 µg and 160/10 µg improved lung function over 24 weeks compared with ICS
monotherapy (which is not a recommended therapy for COPD) and reduced COPD exacerbations
compared with LABA monotherapy. There was a numerical dose response favouring the BFF MDI
320/10 µg dose for all lung function and exacerbation endpoints [11].
The current SOPHOS study (NCT02727660) evaluated lung function (primary objective), COPD
exacerbations (secondary objectives) and safety, following treatment with BFF MDI 320/10 µg, BFF MDI
160/10 µg or formoterol fumarate dihydrate (FF) MDI monotherapy for at least 12, and up to 52, weeks in
patients with moderate-to-very severe COPD who had a documented history of at least one moderate/
severe COPD exacerbation in the previous 12 months.
Material and methods
Patients
Patients (40–80 years of age) were current/former smokers (⩾10 pack-years) with a history of COPD
(defined by American Thoracic Society/European Respiratory Society or locally applicable guidelines) [14]
who remained symptomatic (COPD Assessment Test score ⩾10) despite receiving one or more inhaled
maintenance bronchodilators. Patients were required to have a post-bronchodilator forced expiratory
volume in 1 s (FEV1)/forced vital capacity ratio <0.70, and post-bronchodilator FEV1 ⩾25% to <80%
predicted normal (second screening visit) according to the National Health and Nutrition Examination
Survey III reference equations [15, 16]. Patients had a documented history of at least one moderate/severe
COPD exacerbation in the previous 12 months. Patients with a current diagnosis of asthma were excluded.
Study design
In this double-blind, parallel-group study, patients were screened at 292 centres in 18 countries, and
randomised 1:1:1 using an interactive web response system to receive twice-daily BFF MDI 320/10 μg, BFF
MDI 160/10 μg or FF MDI 10 μg (figure E1). Randomisation was stratified by country, exacerbation
history, post-bronchodilator FEV1 and blood eosinophil count (with enrolment targeted at a 2:1 ratio of
patients with eosinophil counts ⩾150 and <150 cells·mm−3).
Prohibited COPD medications, which included long-acting muscarinic antagonists (LAMAs) and LABAs
(see online data supplement), were discontinued at the start of screening. Patients receiving maintenance ICS
(single inhaler or ICS/LABA) continued the ICS component of treatment throughout the screening period
and discontinued the ICS component at randomisation. Albuterol sulfate (Ventolin HFA; GlaxoSmithKline,
Research Triangle Park, NC, USA) was provided as rescue medication throughout the study.
Patients received 12 to 52 weeks of treatment. The study ended when the last patient remaining in the
study completed 12 weeks of treatment or completed their final visit.
The study adhered to the Declaration of Helsinki, the International Council for Harmonisation/Good Clinical
Practice and applicable regulatory requirements. Patients provided written informed consent. Informed consent
forms were reviewed and approved by an Independent Ethics Committee or Institutional Review Board.
Efficacy endpoints and assessments
Efficacy analyses were based on the modified intent-to-treat (mITT) population (data from all patients who
received any amount of the study drug collected before treatment discontinuation). Endpoints and statistical
analysis approaches differed depending on regional regulatory requirements. This manuscript describes the
analysis using the US approach. Further details of study estimands, analysis populations, statistical analyses,
sample size calculations, definitions of COPD exacerbations and severity, the analysis using the Ex-US
approach, and post hoc and subgroup analyses are provided in the online data supplement.
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The primary endpoint (US registration approach) was the change from baseline in morning pre-dose
trough FEV1 at week 12, analysed using the efficacy estimand. Analysis of the same outcome using an
attributable estimand was the first secondary endpoint.
Further secondary endpoints were: time to first moderate/severe COPD exacerbation; change from baseline
in average daily rescue medication use over 12 weeks; and St George’s Respiratory Questionnaire (SGRQ)
responder rate (percentage of patients achieving a minimal clinically important difference ⩾4 units in total
score) at week 12. The rates of moderate/severe exacerbations were also assessed.
Pre-specified subgroup analyses of the primary endpoint and exacerbation rates were performed according
to baseline blood eosinophil count (<150 versus ⩾150 cells·mm−3) and according to number of moderate/
severe COPD exacerbations in the previous 12 months (1 versus ⩾2). Additional post hoc analyses of
exacerbation rates by ICS use at baseline and by 4-week intervals were also performed.
Safety analyses
Treatment-emergent adverse events (TEAEs) were monitored in the safety population (all randomised
patients who received study drug, even if <1 full dose). Potential major adverse cardiovascular events
(MACE) and pneumonia cases were adjudicated by an external Clinical Endpoint Committee.
Results
Study population
The first patient was randomised in May 2016, and the study completed in April 2018. Of 1876
randomised patients, 1864 (99.4%) were treated (BFF MDI 320/10 µg, n=624; BFF MDI 160/10 µg, n=627;
and FF MDI, n=613), and 1843 (98.2%) were included in both the mITT and safety populations; A total
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FIGURE 1 Patient disposition. A total of 21 subjects had participated in multiple sponsor studies and were excluded from the intent to treat (ITT),
modified ITT (mITT) and safety populations. BFF: budesonide/formoterol fumarate dihydrate; MDI: metered dose inhaler; FF: formoterol fumarate
dihydrate.
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192 (10.2%) patients completed 12, 24 and 52 weeks of treatment, respectively. The mean study duration
was 232.1 days (33.2 weeks). Reasons for study discontinuation are summarised in figure 1.
Demographic characteristics were generally balanced across treatment groups (table 1). Most patients in
the mITT population were white (83.2%) and male (57.0%). The mean±standard deviation age was
64.9±8.3 years, 39.3% of patients were current smokers and the mean±SD smoking history was 45.0±27.1
pack-years. Most patients (76.3%) used ICS at screening. Enrolment had been targeted to achieve a 2:1
ratio for eosinophil subgroups (⩾150 versus <150 cells·mm−3) and, accordingly, 67.2% of patients had a
baseline blood eosinophil count of ⩾150 cells·mm−3 (figure E2). In the 12 months before screening, 38.5%
of patients had two or more moderate/severe exacerbations.
Efficacy analyses
For the primary endpoint of change from baseline in morning pre-dose trough FEV1 at week 12, analysed
using the efficacy estimand, BFF MDI 320/10 µg and 160/10 µg demonstrated statistically significant
TABLE 1 Demographics and baseline characteristics (modified intent-to-treat population)
BFF MDI 320/10 µg BFF MDI 160/10 µg FF MDI 10 µg All patients
Patients, n 619 617 607 1843
Age, years 65.3±8.1 64.5±8.4 64.8±8.5 64.9±8.3
Age ⩾65 years 347 (56.1) 318 (51.5) 334 (55.0) 999 (54.2)
Male 367 (59.3) 345 (55.9) 339 (55.8) 1051 (57.0)
White/black/other, % 83.0/4.8/12.1 83.6/3.6/12.8 83.0/4.8/12.2 83.2/4.4/12.4
Current smoker 257 (41.5) 223 (36.1) 245 (40.4) 725 (39.3)
Number of pack-years smoked 44.2±26.0 45.8±28.0 44.9±27.4 45.0±27.1
Total CAT score# 21.7±6.4 21.3±6.1 21.2±6.3 21.4±6.3
SGRQ total score 51.4±18.2 51.1±17.8 50.7±17.6 51.1±17.8
History of moderate/severe exacerbations
0 exacerbations 5 (0.8) 2 (0.3) 1 (0.2) 8 (0.4)
1 exacerbation 378 (61.1) 374 (60.6) 374 (61.6) 1126 (61.1)
⩾2 exacerbations 236 (38.1) 241 (39.1) 232 (38.2) 709 (38.5)
History of severe exacerbations
0 exacerbations 494 (79.8) 510 (82.7) 497 (81.9) 1501 (81.4)
1 exacerbation 108 (17.4) 96 (15.6) 93 (15.3) 297 (16.1)
⩾2 exacerbations 17 (2.7) 11 (1.8) 17 (2.8) 45 (2.4)
COPD severity
Mild 0 (0.0) 1 (0.2) 1 (0.2) 2 (0.1)
Moderate 338 (54.6) 330 (53.5) 321 (52.9) 989 (53.7)
Severe 241 (38.9) 230 (37.3) 244 (40.2) 715 (38.8)
Very severe 37 (6.0) 56 (9.1) 36 (5.9) 129 (7.0)
COPD duration, years 8.1±6.4 7.7±5.5 7.9±6.2 7.9±6.1
Prior COPD treatment¶
SABA and/or SAMA only, PRN 4 (0.6) 3 (0.5) 1 (0.2) 8 (0.4)
MA only 26 (4.2) 33 (5.3) 30 (4.9) 89 (4.8)
BA only 22 (3.6) 37 (6.0) 39 (6.4) 98 (5.3)
ICS only 12 (1.9) 14 (2.3) 13 (2.1) 39 (2.1)
MA/BA only 83 (13.4) 81 (13.1) 71 (11.7) 235 (12.8)
ICS/BA only 272 (43.9) 264 (42.8) 258 (42.5) 794 (43.1)
ICS/MA only 13 (2.1) 16 (2.6) 17 (2.8) 46 (2.5)
ICS/MA/BA 185 (29.9) 165 (26.7) 177 (29.2) 527 (28.6)
ICS use at screening 482 (77.9) 459 (74.4) 465 (76.6) 1406 (76.3)
Baseline blood eosinophil count
<150 cells·mm−3 197 (31.8) 213 (34.5) 193 (31.8) 603 (32.7)
⩾150 cells·mm−3 422 (68.2) 403 (65.3) 413 (68.0) 1238 (67.2)
Post-bronchodilator FEV1, % predicted 51.09±13.70 50.59±14.27 50.97±13.46 50.88±13.81
Post-bronchodilator reversibility for FEV1, %
+ 12.1±13.0 13.2±14.1 12.9±14.3 12.7±13.8
Rescue medication use, puffs·day-1 3.5±3.2 3.7±3.4 3.6±3.5 3.6±3.4
Data are presented as mean±standard deviation or n (%), unless otherwise stated. BFF: budesonide/formoterol fumarate dihydrate; MDI:
metered dose inhaler; FF: formoterol fumarate dihydrate; CAT: Chronic Obstructive Pulmonary Disease (COPD) Assessment Test; SGRQ: St
George’s Respiratory Questionnaire; SABA: short-acting β2-agonist; SAMA: short-acting muscarinic antagonist; PRN: as needed; MA:
muscarinic antagonist; BA: β2-agonist; ICS: inhaled corticosteroid; FEV1: forced expiratory volume in 1 s.
#: total CAT score was the sum of
eight CAT item scores and could range from 0 to 40; ¶: scheduled use of a SAMA and/or SABA was included in all categories except PRN; +:
reversibility is defined as (change from pre-bronchodilator to post-bronchodilator for FEV1)×100/pre-bronchodilator FEV1.
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improvements versus FF MDI, with least squares mean (LSM) differences of 34 mL (95% confidence
interval [CI] 9–60; p=0.0081) and 32 mL [95% CI 7–57; p=0.0134], respectively (table 2 and fig. 2).
Analysis of the same endpoint for the attributable estimand (secondary analysis) also demonstrated
significant improvements for BFF MDI 320/10 µg and 160/10 µg versus FF MDI (LSM differences 50 mL
[95% CI 24–76, p=0.0002] and 44 mL [95% CI 18–70; p=0.0009], respectively) (table 2).
The time to first moderate/severe COPD exacerbation was significantly longer for BFF MDI 320/10 µg and
BFF MDI 160/10 µg versus FF MDI (hazard ratio [HR] 0.827 [95% CI 0.688–0.995; p=0.0441] and 0.803
[95% CI 0.668–0.966; p=0.0198], respectively) (table 2), with the benefits for both BFF MDI doses versus
FF MDI evident from as early as 4 weeks and throughout the treatment period (fig. 3). In the subgroup of
patients with a history of at least two moderate/severe exacerbations in the last 12 months, BFF MDI 320/
10 µg (n=236) and 160/10 µg (n=241) delayed the time to first exacerbation versus FF MDI (n=232) to a
similar extent compared with the overall population. However, treatment differences did not reach
statistical significance in this smaller patient sample (HR 0.783 [95% CI 0.590–1.039; p=0.0904] and 0.799
[95% CI 0.603–1.059; p=0.1178], respectively).
BFF MDI 320/10 µg and 160/10 µg reduced the rate of moderate/severe COPD exacerbations versus FF
MDI (rate ratios 0.67 [95% CI 0.54–0.82; p=0.0001] and 0.71 [95% CI 0.58–0.87; p=0.0010], respectively;
TABLE 2 Primary, secondary and additional efficacy endpoints (modified intent-to-treat population; efficacy estimand unless
stated otherwise)
BFF MDI 320/10 μg BFF MDI 160/10μg FF MDI 10 µg
Patients, n 619 617 607
Primary endpoint
Change from baseline in morning pre-dose trough FEV1 (mL) at week 12
#
n 542 540 501
LSM±SE 72±9.4 69±9.3 37±9.6
LSM difference versus FF MDI (95% CI) 34 (9–60) 32 (7–57)
p-value 0.0081 0.0134
Secondary endpoints
Change from baseline in morning pre-dose trough FEV1 (mL) at week 12 (attributable estimand)
#
n 612 612 601
LSM±SE 59±9.7 53±9.5 9±10.1
LSM difference versus FF MDI (95% CI) 50 (24–76) 44 (18–70)
p-value 0.0002 0.0009
Time to first moderate/severe COPD exacerbation¶
Patients with exacerbation n (%) 220 (35.5) 223 (36.1) 241 (39.7)
HR versus FF MDI (95% CI) 0.827 (0.688–0.995) 0.803 (0.668–0.966)
p-value 0.0441 0.0198
SGRQ responder rate at week 12+
Responders n (%) 315 (51.98) 331 (54.00) 262 (43.96)
Difference versus FF MDI % (95% CI) 7.55 (1.67–13.43) 11.05 (5.18–16.91)
p-value 0.0121 0.0002
Change from baseline in mean daily rescue medication use (puffs·day-1) over 12 weeks#
n 612 610 599
LSM±SE −0.9±0.09 −0.9±0.09 −0.6±0.09
LSM difference versus FF MDI (95% CI) −0.32 (−0.56 to −0.08) −0.29 (−0.53 to −0.05)
p-value 0.0097 0.0185
Additional endpoints
Rate of moderate/severe exacerbations per year§
Adjusted rate of exacerbations+/−SE 0.93±0.073 0.98±0.076 1.39±0.106
Rate ratio versus FF MDI (95% CI) 0.67 (0.54–0.82) 0.71 (0.58–0.87)
p-value 0.0001ƒ 0.0010ƒ
Time to first moderate/severe COPD exacerbation in patients with a history of ⩾2 COPD exacerbations in the last 12 months§
Patients with exacerbation, n (%) 93 (39.4) 97 (40.2) 106 (45.7)
HR versus FF MDI (95% CI) 0.783 (0.590–1.039) 0.799 (0.603–1.059)
p-value 0.0904 0.1178
BFF: budesonide/formoterol fumarate dihydrate; MDI: metered dose inhaler; FF: formoterol fumarate dihydrate; FEV1: forced expiratory
volume in 1 s; LSM: least squares mean; HR: hazard ratio; SGRQ: St George’s Respiratory Questionnaire; COPD: chronic obstructive pulmonary
disease. #: analysed by repeated measures linear mixed model; ¶: analysed by Cox regression; +: analysed by logistic regression model;
§: analysed by negative binomial regression. Rate of exacerbations per year=total number of exacerbations / total years of exposure across all
patients for the treatment. ƒ: p-values for this endpoint are considered nominal since these analyses were not under Type I error control.
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these endpoints were not included in the Type I error control strategy, so were nominally significant)
(table 2).
Both BFF MDI doses significantly reduced mean daily rescue medication use over 12 weeks and
significantly increased SGRQ responder rates at week 12 versus treatment with FF MDI alone (table 2).
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FIGURE 2 Primary efficacy endpoint: adjusted mean change from baseline in morning pre-dose trough forced
expiratory volume in 1 s (FEV1) over time (modified intent-to-treat population; efficacy estimand). Error bars
represent the standard error. BFF: budesonide/formoterol fumarate dihydrate; MDI: metered dose inhaler;
FF: formoterol fumarate dihydrate.
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FIGURE 3 Time to first moderate/severe chronic obstructive pulmonary disease (COPD) exacerbation (modified intent-to-treat population; efficacy
estimand). BFF: budesonide/formoterol fumarate dihydrate; MDI: metered dose inhaler; FF: formoterol fumarate dihydrate.
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Pre-specified subgroup analyses suggested that the improvements in morning pre-dose trough FEV1 at
week 12 and reductions in the rate of moderate/severe COPD exacerbations with both doses of BFF MDI
compared with FF MDI were driven by patients with a baseline blood eosinophil count ⩾150 cells·mm−3
(fig. 4). Further analysis of lung function response by continuous baseline eosinophil count with locally
weighted scatterplot smoothing (LOESS) curves showed that improvements in morning pre-dose trough
FEV1 for BFF MDI 320/10 µg versus FF MDI at week 12 began at blood eosinophil levels of approximately
100–150 cells·mm−3. Results for BFF MDI 160/10 µg versus FF MDI were consistent with these findings
up to eosinophil counts of approximately 350 cells·mm−3, after which improvements to lung function with
BFF MDI 160/10 µg began to decrease (fig. 5a and b). LOESS curves of BFF MDI 320/10 µg and BFF MDI
160/10 µg showed that the two doses began to diverge from each other at blood eosinophil levels of
approximately 350–400 cells·mm−3, with the treatment difference between the two doses exceeding 20 mL
from approximately 450 cells·mm−3 (fig. 5c). Analysis of the rate of moderate/severe exacerbations by
continuous baseline eosinophil count showed numerical improvements with both doses of BFF MDI
versus FF MDI began at blood eosinophil levels of approximately 100–150 cells·mm−3 and were
maintained with increasing eosinophil levels (fig. 5d and e). With both BFF MDI doses, improvements in
the rate of moderate or severe COPD exacerbations increased with increasing blood eosinophil levels.
When plotted together, the BFF MDI doses began to diverge from each other at blood eosinophil levels of
approximately 150–200 cells·mm−3, with a treatment difference between the two doses exceeding 15% at
blood eosinophil levels above approximately 250–300 cells·mm−3 (fig. 5f ).
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FIGURE 4 Change from baseline in morning pre-dose trough forced expiratory volume in 1 s (FEV1) at week 12,
a) and rate of moderate/severe chronic obstructive pulmonary disease (COPD) exacerbations, b) by baseline
eosinophil count (modified intent-to-treat population; efficacy estimand). Error bars represent 95% confidence
intervals. BFF: budesonide/formoterol fumarate dihydrate; MDI: metered dose inhaler; FF: formoterol fumarate
dihydrate.
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Subgroup analyses based on the number of moderate/severe exacerbations in the year before the study
showed that improvements in lung function and exacerbation rates were similar in patients with a history
of one moderate/severe exacerbation and those with at least two moderate/severe exacerbations (figure E3).
Post hoc analyses of the rate of moderate/severe exacerbations by ICS use prior to study entry
demonstrated the benefit of ICS in all patients regardless of ICS usage prior to study entry. In an analysis
that estimated the rate of exacerbations for each 4-week period, both BFF MDI doses separated from FF
MDI during the first 4 months and the last 5 months of the treatment period, with some overlap during
the mid-portion of the treatment period. Further details are provided in the online data supplement.
Safety
The incidence of TEAEs (table 3) was similar across treatment groups (BFF MDI 320/10 µg, 48.0%; BFF
MDI 160/10 µg, 50.9%; FF MDI, 50.2%). Most TEAEs were mild or moderate, and few patients (4.4%)
experienced a TEAE that was considered to be drug related. The incidence of serious TEAEs was highest
for FF MDI (13.7%), followed by BFF MDI 160/10 µg (12.6%) and BFF MDI 320/10 µg (9.7%); few
serious TEAEs (0.2%) were considered to be drug related. The incidences of TEAEs and serious TEAEs
leading to study drug discontinuation were similar across the treatment groups.
There were 22 deaths in the study (15 on-treatment, i.e. due to adverse events that started during the
treatment period, and seven post-treatment). The highest number of on-treatment deaths occurred in the
FF MDI group (n=8), followed by BFF MDI 160/10 µg (n=4) and BFF MDI 320/10 µg (n=3). No deaths
were considered to be drug related. Details of the causes of death are provided in the online data
supplement.
The incidence of confirmed pneumonia was 1.6% in the BFF MDI 320/10 μg group (n=10), 2.4% in the
BFF MDI 160/10 µg group (n=15) and 2.3% in the FF MDI group (n=14). The proportion of patients with
confirmed pneumonia was lowest in the BFF MDI 320/10 µg group over all time periods (12, 24, 36 and
52 weeks; table E1). Overall, 27 patients (1.5%) had confirmed pneumonia that was considered a serious
TEAE.
Nine patients experienced TEAEs (BFF MDI 160/10 µg, n=3 [0.5%]; FF MDI, n=6 [1.0%]) that were
confirmed as MACE (none in the BFF MDI 320/10 µg group).
Discussion
The SOPHOS study aimed to evaluate the efficacy and safety of BFF MDI 320/10 µg and 160/10 µg in
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FIGURE 5 Lung function and exacerbation responses by blood eosinophil counts (efficacy estimand, modified intent-to-treat population). Change
from baseline in morning pre-dose trough forced expiratory volume in 1 s (FEV1) (mL) at week 12 by blood eosinophil count, for a) budesonide/
formoterol fumarate dihydrate (BFF) metered dose inhaler (MDI) 320/10 µg versus formoterol fumarate dihydrate (FF) MDI 10 µg, b) BFF MDI 160/
10 µg versus FF MDI 10 µg, and c) BFF MDI 320/10 µg versus BFF MDI 160/10 µg, and rate of moderate/severe COPD exacerbations by blood
eosinophil count for d) BFF MDI 320/10 µg versus FF MDI 10 µg, e) BFF MDI 160/10 µg versus FF MDI 10 µg, and f) BFF MDI 320/10 µg versus BFF
MDI 160/10 µg. The banded areas represent 95% confidence intervals. COPD: chronic obstructive pulmonary disease.
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exacerbations. Both doses of BFF MDI resulted in statistically significant improvements in lung function
(primary efficacy endpoint) compared with FF MDI. Also, both doses of BFF MDI resulted in significant
improvements in all secondary efficacy endpoints, including time to first moderate/severe exacerbation,
and both doses reduced the rate of moderate/severe exacerbations, versus FF MDI. The small numerical
dose response favouring BFF MDI 320/10 µg for improvements to lung function (trough FEV1) and for
reducing exacerbation rates in the overall study population appeared to be more pronounced as blood
eosinophil levels increased, with the doses diverging above approximately 350–400 cells and 150–200 cells
for trough FEV1 and exacerbation rates, respectively. Results for the Ex-US analysis approach that are
provided in the online data supplement were similar to the results for the US analysis approach that are
presented in this manuscript.
Our findings were well aligned with the results of TELOS (NCT02766608), a 24-week study investigating the
therapeutic effects of BFF MDI 320/10 µg and 160/10 µg relative to treatment with monocomponents in
patients with moderate-to-very severe COPD [11]. In TELOS, both doses of BFF MDI also showed
superiority to FF MDI monotherapy, with a dose-related response for lung function and exacerbation
endpoints. However, while >70% of patients in TELOS did not have a moderate/severe COPD exacerbation
in the year before the study, SOPHOS specifically enrolled patients with a documented history of moderate/
severe exacerbations in the year prior to the study. As expected given the differences in the patient
population, the exacerbation rates in SOPHOS were considerably higher than those in TELOS, but the
treatment effect of BFF MDI compared with FF MDI, as assessed by the rate ratio for COPD exacerbations,
was very similar in both studies. For patients who continued treatment beyond 24 weeks and up to 52 weeks,
the effects of BFF MDI on exacerbation risk seen in the first 24 weeks of treatment were sustained over the
entire treatment period. Hence, SOPHOS confirmed the efficacy of BFF MDI in a population known to be
at risk of exacerbations (i.e. in a population for which ICS/LABA is a recommended treatment option to
prevent further exacerbations [1]) over a treatment period of 12 to 52 weeks.
A pre-defined subgroup analysis according to baseline blood eosinophil count showed that improvements
in lung function and reductions in exacerbation rates were driven by patients with baseline blood
eosinophil counts ⩾150 cells·mm−3. These findings were generally comparable to the TELOS study [11],
which included a similar eosinophil subgroup analysis. The relationship between blood eosinophil levels
and response to ICS-containing therapies, with regards to reducing exacerbation risk, has also been
described in other recent studies [17–21], suggesting that patients with higher eosinophil counts may
TABLE 3 Treatment-emergent adverse events (TEAEs) (safety population)
BFF MDI 320/10 μg BFF MDI 160/10 μg FF MDI 10 μg All patients
Patients, n 619 617 607 1843
⩾1 TEAE 297 (48.0), 819 314 (50.9), 919 305 (50.2), 932 916 (49.7), 2670
Mild 124 (20.0) 116 (18.8) 106 (17.5) 346 (18.8)
Moderate 118 (19.1) 135 (21.9) 119 (19.6) 372 (20.2)
Severe 55 (8.9) 63 (10.2) 80 (13.2) 198 (10.7)
Drug-related TEAEs# 31 (5.0), 43 26 (4.2), 35 24 (4.0), 33 81 (4.4), 111
Serious TEAEs¶ 60 (9.7), 88 78 (12.6), 110 83 (13.7), 151 221 (12.0), 349
Drug-related serious TEAEs 1 (0.2), 2 1 (0.2), 1 1 (0.2), 1 3 (0.2), 4
TEAEs leading to early discontinuation 28 (4.5), 35 21 (3.4), 29 33 (5.4), 42 82 (4.4), 106
Serious TEAEs leading to early discontinuation 17 (2.7), 18 16 (2.6), 17 22 (3.6), 25 55 (3.0), 60
Deaths (all causes)
On-treatment 3 (0.5) 4 (0.6) 8 (1.3) 15 (0.8)
Post-treatment 3 (0.5) 4 (0.6) 0 (0.0) 7 (0.4)
TEAEs occurring in ⩾4% of patients in any treatment arm (preferred term)
Nasopharyngitis 41 (6.6), 53 53 (8.6), 61 36 (5.9), 43 130 (7.1), 157
COPD 27 (4.4), 32 30 (4.9), 33 50 (8.2), 65 107 (5.8), 130
Upper respiratory tract infection 28 (4.5), 29 14 (2.3), 18 24 (4.0), 28 66 (3.6), 75
Confirmed MACE as determined by CEC 0 (0.0), 0 3 (0.5), 3 6 (1.0), 6 9 (0.5), 9
Confirmed pneumonia as determined by CEC 10 (1.6), 11 15 (2.4), 15 14 (2.3), 15 39 (2.1), 41
Serious confirmed pneumonia events 8 (1.3), 8 11 (1.8), 11 8 (1.3), 9 27 (1.5), 28
Data are presented as n (%), events or n (%), unless otherwise stated. BFF: budesonide/formoterol fumarate dihydrate; MDI: metered dose
inhaler; FF: formoterol fumarate dihydrate; COPD: chronic obstructive pulmonary disease; MACE: major adverse cardiovascular event; CEC:
Clinical Endpoint Committee. #: relationship determined by investigator assessment; ¶: TEAE leading to death, hospitalisation or a life-threatening
TEAE.
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experience greater therapeutic benefits from ICS than patients with lower eosinophil counts. Our emerging
understanding of how eosinophils affect responses to ICS treatment is now also being reflected in the most
recent GOLD report [1]. This recommends considering combination therapy with an ICS/LABA for
patients who experience one exacerbation per year despite long-acting bronchodilator treatment if they
have blood eosinophil levels ⩾300 cells·mm−3, and for patients who experience two or more moderate
COPD exacerbations per year (or at least one severe COPD exacerbation leading to hospitalisation) if they
have eosinophil levels ⩾100 cells·mm−3. In our study, in which 61.1% of patients had one moderate/severe
exacerbation in the year prior to the study (and the other 39.9% of patients had two or more), enrichment
for patients with baseline blood eosinophils ⩾150 cells·mm−3 allowed for a detailed analysis of lung
function and exacerbations by continuous eosinophil counts. This analysis showed that with both doses,
benefits on lung function and exacerbations for BFF MDI versus FF MDI were evident over a broad range
of blood eosinophil levels, with numerical improvements beginning at approximately 100–150 cells·mm−3.
In addition, our analysis by continuous baseline eosinophil count showed that a dose response favouring
BFF MDI 320/10 µg was evident from blood eosinophil levels of approximately 450 cells·mm−3 for lung
function endpoints and approximately 250 cells·mm−3 for exacerbation rates. These data suggest that there
is the potential for patients with COPD to derive benefit from more than one ICS dose and that overall
ICS dose response is influenced appreciably by eosinophil levels. These hypotheses will be prospectively
evaluated in the recently completed ETHOS study [22]. Finally, subgroup analyses based on the number of
moderate/severe COPD exacerbations (1 or ⩾2) in the prior year showed that the benefits on lung
function and exacerbation rates for BFF MDI versus FF MDI were not affected by the number of
exacerbations in the year before the study.
To minimise the potential for a run-in bias [23] patients in our study who were using ICS prior to the
study entry continued the ICS during the screening period until randomisation. Additional analysis of
exacerbation rates for each 4-week period of treatment indicated that the benefit of BFF MDI on
exacerbations was not driven solely by acute ICS withdrawal in the first month after randomisation, as
suggested for recent trials comparing triple therapy with LAMA/LABA dual therapies [24].
BFF MDI 320/10 μg and 160/10 μg were well tolerated in this 12–52 week study, with no new or
unexpected safety findings or dose-related effects on the pattern or frequency of TEAEs, which confirmed
the findings from the 24-week TELOS study [11]. ICS use in patients with COPD has been associated with
an increased risk of pneumonia [1, 25, 26]. However, there is evidence to suggest that the pneumonia risk
with treatments containing budesonide may be lower compared with other ICS components [27–29], and
a recent pooled analysis found no significant increase in the risk of pneumonia when comparing
budesonide-containing with non-budesonide-containing treatments [30]. In the present study, the
percentage of patients with confirmed pneumonia events was 2.1% overall, and lowest in the BFF MDI
320/10 µg group (1.6%); this was similar to the results of TELOS and also the KRONOS study, neither of
which showed a higher incidence of pneumonia in their budesonide-containing treatment arms relative to
non-budesonide-containing treatment arms [11, 31]. As in the TELOS study, no ICS dose-related effect on
the incidence of pneumonia was observed in this present study [11].
A potential limitation of SOPHOS was the variable length study design and the correspondingly small
proportion of patients (10.2%) who completed 52 weeks of treatment. However, the effects of BFF MDI on
exacerbation risk observed in the first 24 weeks of treatment were sustained after 24 weeks, and were
comparable to those observed with a different formulation of BFF versus FF over 6 months [4]. Since only
a small portion of patients completed 12 months of treatment, the study may not be optimal for assessing
risk of exacerbations over the long term. However, patients in this study were recruited over an 18-month
period and all seasons were well represented, reducing the potential impact of seasonal variation on
exacerbation rates.
In conclusion, the SOPHOS study extended the findings from the TELOS study by demonstrating the
efficacy and safety of BFF MDI, formulated using co-suspension delivery technology, in the key target
population for ICS/LABA treatment; i.e. patients with a history of COPD exacerbations, over a treatment
period of 12 to 52 weeks. BFF MDI 320/10 µg and 160/10 µg both improved lung function and reduced
exacerbation risk compared to FF MDI monotherapy, with a dose response favouring the BFF MDI 320/
9.6 µg dose at elevated blood eosinophil levels. Both doses of BFF MDI were well tolerated, and there was
no ICS dose-related effect on safety outcomes, including the incidence of confirmed pneumonia events.
The study findings confirm that BFF MDI was an effective treatment for the management of COPD in
patients who had a prior exacerbation history.
Acknowledgements: The authors would like to thank all the patients and their families, and the team of investigators,
research nurses and operations staff involved in these studies. These data were presented at the American Thoracic
Society International Conference, Dallas, TX, USA; May 2019.
https://doi.org/10.1183/23120541.00187-2019 10
COPD | N.A. HANANIA ET AL.
Author contributions: All authors contributed to study conception and design, and interpretation of the data. N.A.
Hanania, A. Papi and F.J. Martinez contributed to data acquisition. K.A. Rossman, C.S. Cappelletti, E.A. Duncan, J.S.
Nyberg and P.M. Dorinsky contributed to the data analysis. All authors reviewed and provided feedback on each draft
of the manuscript; approved the final draft for publication; and assume accountability for all aspects of the work.
Support statement: This study was supported by AstraZeneca. Medical writing support, under the direction of the
authors, was provided by Joanna Wilson and Thomas Owens of CMC Connect, a division of McCann Health Medical
Communications Ltd, Manchester, UK, funded by AstraZeneca, Gaithersburg, FL, USA in accordance with Good
Publication Practice (GPP3) guidelines. Funding information for this article has been deposited with the Crossref
Funder Registry.
Conflict of interest: N.A. Hanania has received personal fees for serving on advisory boards or as a consultant for
AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Mylan, Novartis, Sanofi Genzyme and Sunovion; his institution
has received research grant support on his behalf from AstraZeneca, Boehringer Ingelheim and GlaxoSmithKline. A.
Papi reports board membership, consultancy, payment for lectures, grants for research and travel expenses
reimbursement from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mundipharma and TEVA; payment
for lectures and travel expenses reimbursement from Menarini, Novartis and Zambon; board membership, payment for
lectures, grants for research and travel expenses reimbursement from Pfizer; and grants from Sanofi, outside the
submitted work. A. Anzueto reports personal fees for consultancy from AstraZeneca, Boehringer Ingelheim,
GlaxoSmithKline, Novartis and Sunovion Pharmaceutical; and a research grant to University of Texas Health, San
Antonio, from GlaxoSmithKline, outside the submitted work. F.J. Martinez reports personal fees, nonfinancial support
and other from Boehringer Ingelheim during the conduct of the study; personal fees and nonfinancial support from the
American College of Chest Physicians, AstraZeneca, Boehringer Ingelheim, Canadian Respiratory Network, Chiesi,
ConCert, Continuing Education, Genentech, GlaxoSmithKline, Inova Fairfax Health System, Miller Communications,
the National Association for Continuing Education, Novartis, Pearl Pharmaceuticals, PeerView Communications,
Physicians Education Resource, Potomac, Prime Communications, the Puerto Rican Respiratory Society, Roche,
Rockpointe, Sunovion, Teva, Theravance, Unity, University of Alabama Birmingham, UpToDate, WebMD/Medscape
and the Western Connecticut Health Network; nonfinancial support from Gilead, Nitto, ProterixBio and Zambon;
personal fees from Academic CME, the American Thoracic Society, Columbia University, Integritas, MD Magazine,
Methodist Hospital Brooklyn, New York University, Patara, PlatformIQ; other from Afferent/Merck, Bayer, Biogen,
Bridge Biotherapeutics, Prometic and Veracyte; grants from the NIH, Promedior and Rare Disease Healthcare
Communications. K.A. Rossman is a full-time employee of AstraZeneca. C.S. Cappelletti is a full-time employee of
AstraZeneca. E.A. Duncan is a full-time employee of AstraZeneca. J.S. Nyberg is a former employee of AstraZeneca.
P.M. Dorinsky is a full-time employee of AstraZeneca.
References
1 Global Initiative for Chronic Obstructive Lung Disease. 2019 Report: Global Strategy for the Diagnosis,
Management and Prevention of COPD. https://goldcopd.org. Date last accessed: 28 October 2019.
2 Anzueto A, Ferguson GT, Feldman G, et al. Effect of fluticasone propionate/salmeterol (250/50) on COPD
exacerbations and impact on patient outcomes. COPD 2009; 6: 320–329.
3 Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic
obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449–456.
4 Ferguson GT, Tashkin DP, Skärby T, et al. Effect of budesonide/formoterol pressurized metered-dose inhaler on
exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE
(Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study. Respir Med 2017; 132: 31–41.
5 Sharafkhaneh A, Southard JG, Goldman M, et al. Effect of budesonide/formoterol pMDI on COPD exacerbations:
a double-blind, randomized study. Respir Med 2012; 106: 257–268.
6 Tashkin DP, Rennard SI, Martin P, et al. Efficacy and safety of budesonide and formoterol in one pressurized
metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a
6-month randomized clinical trial. Drugs 2008; 68: 1975–2000.
7 Rennard SI, Tashkin DP, McElhattan J, et al. Efficacy and tolerability of budesonide/formoterol in one
hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease:
results from a 1-year randomized controlled clinical trial. Drugs 2009; 69: 549–565.
8 Calverley P, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic
obstructive pulmonary disease. Eur Respir J 2003; 22: 912–919.
9 Fukuchi Y, Samoro R, Fassakhov R, et al. Budesonide/formoterol via Turbuhaler® versus formoterol via
Turbuhaler® in patients with moderate to severe chronic obstructive pulmonary disease: phase III multinational
study results. Respirology 2013; 18: 866–873. 10.1111/resp.12090.
10 Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of
chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 74–81.
11 Ferguson GT, Papi A, Anzueto A, et al. Budesonide/formoterol MDI with co-suspension delivery technology in
COPD: the TELOS study. Eur Respir J 2018; 52: 1801334.
12 Doty A, Schroeder J, Vang K, et al. Drug delivery from an innovative LAMA/LABA co-suspension delivery
technology fixed-dose combination MDI: evidence of consistency, robustness, and reliability. AAPS PharmSciTech
2018; 19: 837–844.
13 Vehring R, Lechuga-Ballesteros D, Joshi V, et al. Cosuspensions of microcrystals and engineered microparticles for
uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalers. Langmuir 2012;
28: 15015–15023.
14 Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a
summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932–946.
15 Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S.
population. Am J Respir Crit Care Med 1999; 159: 179–187.
https://doi.org/10.1183/23120541.00187-2019 11
COPD | N.A. HANANIA ET AL.
16 Centers for Disease Control and Prevention National Center for Health Statistics. Third National Health and
Nutrition Examination Survey III Spirometry Procedure Manual. wwwn.cdc.gov/nchs/data/nhanes3/manuals/spiro.
pdf. Date last accessed: November 8 2018.
17 Pascoe S, Locantore N, Dransfield MT, et al. Blood eosinophil counts, exacerbations, and response to the addition
of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary
analysis of data from two parallel randomised controlled trials. Lancet Respir Med 2015; 3: 435–442.
18 Watz H, Tetzlaff K, Wouters EFM, et al. Blood eosinophil count and exacerbations in severe chronic obstructive
pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet
Respir Med 2016; 4: 390–398.
19 Bafadhel M, Peterson S, De Blas MA, et al. Predictors of exacerbation risk and response to budesonide in patients
with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med
2018; 6: 117–126.
20 Yun JH, Lamb A, Chase R, et al. Blood eosinophil count thresholds and exacerbations in patients with chronic
obstructive pulmonary disease. J Allergy Clin Immunol 2018; 141: 2037–2047.e2010.
21 Siddiqui SH, Guasconi A, Vestbo J, et al. Blood eosinophils: a biomarker of response to extrafine beclomethasone/
formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015; 192: 523–525.
22 Rabe KF, Martinez FJ, Ferguson GT, et al. A Phase III study of triple therapy with budesonide/glycopyrrolate/
formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery
technology in moderate-to-very severe COPD: the ETHOS study protocol. Respir Med 2019; 158: 59–66.
23 Suissa S. Run-in bias in randomised trials: the case of COPD medications. Eur Respir J 2017; 49: 1700361.
24 Suissa S, Ariel A. Triple therapy trials in COPD: a precision medicine opportunity. Eur Respir J 2018; 52: 1801848.
10.1183/13993003.01848-2018.
25 Ernst P, Gonzalez AV, Brassard P, et al. Inhaled corticosteroid use in chronic obstructive pulmonary disease and
the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007; 176: 162–166.
26 Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic
obstructive pulmonary disease. N Engl J Med 2007; 356: 775–789.
27 Suissa S, Patenaude V, Lapi F, et al. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax
2013; 68: 1029–1036.
28 Janson C, Larsson K, Lisspers KH, et al. Pneumonia and pneumonia related mortality in patients with COPD
treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort
study (PATHOS). BMJ 2013; 346: f3306.
29 Janson C, Stratelis G, Miller-Larsson A, et al. Scientific rationale for the possible inhaled corticosteroid intraclass
difference in the risk of pneumonia in COPD. Int J Chron Obstruct Pulmon Dis 2017; 12: 3055–3064.
30 Hollis S, Jorup C, Lythgoe D, et al. Risk of pneumonia with budesonide-containing treatments in COPD: an
individual patient-level pooled analysis of interventional studies. Int J Chron Obstruct Pulmon Dis 2017; 12:
1071–1084.
31 Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate
with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease
(KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med
2018; 6: 747–758.
https://doi.org/10.1183/23120541.00187-2019 12
COPD | N.A. HANANIA ET AL.
